Postoperative tolvaptan use in left ventricular assist device patients: The TOLVAD randomized pilot study

Purpose Tolvaptan, a selective vasopressin type‐2 antagonist, has been shown to increase serum sodium (Na) and urine output in hyponatremic left ventricular assist device (LVAD) patients in retrospective studies. In this prospective randomized pilot study, we aimed to assess the efficacy of tolvapta...

Full description

Saved in:
Bibliographic Details
Published in:Artificial organs 2022-12, Vol.46 (12), p.2382-2390
Main Authors: Belkin, Mark N., Imamura, Teruhiko, Rodgers, Daniel, Kanelidis, Anthony J., Henry, Michael P., Fujino, Takeo, Kagan, Viktoriya, Meehan, Karen, Okray, Justin, Creighton, Shana, LaBuhn, Colleen, Song, Tae, Ota, Takeyoshi, Jeevanandam, Valluvan, Nguyen, Ann B., Chung, Ben B., Smith, Bryan A., Kalantari, Sara, Grinstein, Jonathan, Sarswat, Nitasha, Pinney, Sean P., Sayer, Gabriel, Kim, Gene, Uriel, Nir
Format: Article
Language:English
Subjects:
Cardiomyopathy
diuretics
Epidermal growth factor receptors
Glomerular filtration rate
Heart
heart failure
Hyponatremia
Ischemia
LVAD
Randomization
Renal function
Sodium
Urine
Vasopressin
Ventricle
Ventricular assist devices
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Purpose Tolvaptan, a selective vasopressin type‐2 antagonist, has been shown to increase serum sodium (Na) and urine output in hyponatremic left ventricular assist device (LVAD) patients in retrospective studies. In this prospective randomized pilot study, we aimed to assess the efficacy of tolvaptan in this population. Methods We conducted a prospective, randomized, non‐blinded pilot study of LVAD recipients with post‐operative hyponatremia (Na 
ISSN:0160-564X
1525-1594
1525-1594
DOI:10.1111/aor.14375